Private Wealth Partners LLC Cuts Stake in Boston Scientific Co. (NYSE:BSX)

Private Wealth Partners LLC lessened its stake in Boston Scientific Co. (NYSE:BSX) by 1.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 228,316 shares of the medical equipment provider’s stock after selling 3,895 shares during the quarter. Boston Scientific makes up 1.6% of Private Wealth Partners LLC’s holdings, making the stock its 20th largest holding. Private Wealth Partners LLC’s holdings in Boston Scientific were worth $20,393,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. TFC Financial Management Inc. raised its holdings in Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 210 shares during the last quarter. Values First Advisors Inc. bought a new stake in shares of Boston Scientific during the third quarter valued at approximately $28,000. Dunhill Financial LLC raised its holdings in Boston Scientific by 86.4% in the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 152 shares during the last quarter. Global Wealth Strategies & Associates lifted its position in Boston Scientific by 423.7% in the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 250 shares in the last quarter. Finally, West Oak Capital LLC purchased a new stake in Boston Scientific during the 4th quarter valued at $29,000. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Citigroup boosted their price target on Boston Scientific from $107.00 to $122.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Royal Bank of Canada upped their target price on shares of Boston Scientific from $105.00 to $116.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. StockNews.com upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday, January 29th. Piper Sandler increased their price objective on shares of Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Finally, Canaccord Genuity Group lifted their target price on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. One equities research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $107.39.

Boston Scientific Trading Up 0.3 %

Boston Scientific stock opened at $105.63 on Thursday. Boston Scientific Co. has a 12-month low of $65.33 and a 12-month high of $107.17. The firm has a market capitalization of $155.68 billion, a price-to-earnings ratio of 84.50, a P/E/G ratio of 2.81 and a beta of 0.80. The firm has a 50 day moving average of $97.39 and a 200 day moving average of $88.94. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. As a group, research analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the sale, the executive vice president now directly owns 29,308 shares of the company’s stock, valued at $2,660,580.24. This trade represents a 19.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP John Bradley Sorenson sold 1,201 shares of Boston Scientific stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $106.31, for a total transaction of $127,678.31. Following the sale, the executive vice president now owns 25,443 shares in the company, valued at approximately $2,704,845.33. The trade was a 4.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 153,640 shares of company stock valued at $15,718,289 over the last ninety days. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.